MX2024005415A - Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados. - Google Patents
Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados.Info
- Publication number
- MX2024005415A MX2024005415A MX2024005415A MX2024005415A MX2024005415A MX 2024005415 A MX2024005415 A MX 2024005415A MX 2024005415 A MX2024005415 A MX 2024005415A MX 2024005415 A MX2024005415 A MX 2024005415A MX 2024005415 A MX2024005415 A MX 2024005415A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- antibodies
- humanized anti
- cell
- prophylactic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163276363P | 2021-11-05 | 2021-11-05 | |
| PCT/US2022/079072 WO2023081652A1 (en) | 2021-11-05 | 2022-11-01 | Pharmaceutical compositions of humanized anti-cd40 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005415A true MX2024005415A (es) | 2024-07-30 |
Family
ID=86242030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005415A MX2024005415A (es) | 2021-11-05 | 2022-11-01 | Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20230279135A1 (https=) |
| EP (1) | EP4426744A4 (https=) |
| JP (1) | JP2024540377A (https=) |
| KR (1) | KR20240095255A (https=) |
| CN (1) | CN118382640A (https=) |
| AU (1) | AU2022381078A1 (https=) |
| CA (1) | CA3236827A1 (https=) |
| MX (1) | MX2024005415A (https=) |
| WO (1) | WO2023081652A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112018004296B1 (pt) | 2015-09-04 | 2020-05-05 | Primatope Therapeutics Inc | anticorpos anti-cd40 humanizados e usos dos mesmos |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| US20250276092A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| WO2025184603A2 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR060487A1 (es) * | 2006-04-21 | 2008-06-18 | Xoma Technology Ltd | Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40 |
| BR112018004296B1 (pt) * | 2015-09-04 | 2020-05-05 | Primatope Therapeutics Inc | anticorpos anti-cd40 humanizados e usos dos mesmos |
-
2022
- 2022-11-01 US US18/051,807 patent/US20230279135A1/en not_active Abandoned
- 2022-11-01 WO PCT/US2022/079072 patent/WO2023081652A1/en not_active Ceased
- 2022-11-01 JP JP2024526890A patent/JP2024540377A/ja active Pending
- 2022-11-01 KR KR1020247016673A patent/KR20240095255A/ko active Pending
- 2022-11-01 CA CA3236827A patent/CA3236827A1/en active Pending
- 2022-11-01 EP EP22890984.2A patent/EP4426744A4/en active Pending
- 2022-11-01 MX MX2024005415A patent/MX2024005415A/es unknown
- 2022-11-01 AU AU2022381078A patent/AU2022381078A1/en active Pending
- 2022-11-01 CN CN202280075264.6A patent/CN118382640A/zh active Pending
-
2025
- 2025-05-23 US US19/216,990 patent/US20250282884A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240095255A (ko) | 2024-06-25 |
| JP2024540377A (ja) | 2024-10-31 |
| EP4426744A4 (en) | 2025-10-22 |
| WO2023081652A1 (en) | 2023-05-11 |
| US20230279135A1 (en) | 2023-09-07 |
| EP4426744A1 (en) | 2024-09-11 |
| AU2022381078A1 (en) | 2024-05-23 |
| US20250282884A1 (en) | 2025-09-11 |
| CN118382640A (zh) | 2024-07-23 |
| CA3236827A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024005415A (es) | Composiciones farmaceuticas de anticuerpos anti-cd40 humanizados. | |
| CR20180484A (es) | Moléculas de unón b7-h3 novedosas, conjugados anticuerpos-fármaco de los mismos y métodos de uso de los mismos | |
| AR127010A2 (es) | Anticuerpo, moléculas relacionadas, célula huesped, método de preparación y composición farmacéutica | |
| CL2021001706A1 (es) | Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326) | |
| MX2024001205A (es) | Combinaciones de agonistas de receptores de hormona tiroidea (tr-\03b2) con compuestos antifibroticos para usarse en tratar enfermedades del higado graso. | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| RU2018134595A (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
| MX2018002708A (es) | Anticuerpos anti-cd40 humanizados y usos de los mismos. | |
| ME02533B (me) | BISPECIFIČNA ANTITELA PROTIV CD3-EPSILON l BCMA | |
| PE20211396A1 (es) | Receptores quimericos de dll3 y metodos para su uso | |
| CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
| CO6640239A2 (es) | Proceso par preparar una composición de inmunoglobulina | |
| RU2016115866A (ru) | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи | |
| BR112017016434A8 (pt) | Cristal de um anticorpo monoclonal anti-pd-1, métodos para produzir cristais de um anticorpo monoclonal anti-pd-1 e para cristalizar um anticorpo monoclonal anti-pd-1, bem como e composição farmacêutica e seu uso | |
| AR086823A1 (es) | Formulaciones de anticuerpo anti-c-met, metodos | |
| RU2015110981A (ru) | Комбинации и их применение | |
| PE20091655A1 (es) | Farmaco para el cancer de higado | |
| MX380191B (es) | Combinaciones de modalidades para el tratamiento de la diabetes. | |
| AR125473A1 (es) | Conjugados de anticuerpo anti-c-met y fármaco | |
| MX2024005727A (es) | Formulaciones estables que comprenden un anticuerpo biespecifico para bcma/cd3. | |
| CL2024002016A1 (es) | Anticuerpo modificado anti-pd-l1 humano; composición farmacéutica; y uso para tratar una enfermedad neurodegenerativa. | |
| SA522432999B1 (ar) | C-17 مركبات تراي تريبينويد تخليقية ذات مجموعات استبدال اساسها نيتروجين عند وطرق استخدامها | |
| NI201700077A (es) | Ácidos piridil-cicloalquil-carboxílico sustituidos, composiciones que los contienen y usos de los mismos. | |
| IN2014DN03077A (https=) | ||
| MX2025009913A (es) | Anticuerpos anti-cd3 y metodos para su uso |